ClinicalTrials.gg
CompletedNCT03328507Updated Oct 24, 2023Results posted

A Pilot Evaluation of BLI4900 Bowel Preparation in Adult Subjects

A Phase 2 interventional study of BLI4900 and PEG Control in Colonoscopy, sponsored by Braintree Laboratories. Completed at 4 sites in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2023-10-24.

Sponsored by Braintree Laboratories (part of Sebela Pharmaceuticals) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
121
Allocation
Non-randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

The objective of this study is to evaluate the safety and efficacy of BLI4900 as a bowel preparation prior to colonoscopy in adult patients.

02

Conditions studied

  • Colonoscopy
03

In context

Lead sponsor

Braintree Laboratories is the lead sponsor of 49 studies on the registry; none are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 7 (70%) have results posted.

First submitted before Braintree Laboratories became part of Sebela Pharmaceuticals.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female outpatients who are undergoing colonoscopy for a routinely accepted indication.
  • 18 to 85 years of age (inclusive).
  • If female, and of , is using an acceptable form of (hormonal birth control, IUD, double-barrier method, depot contraceptive, abstinent, or vasectomized spouse).
  • Negative urine pregnancy test at screening, if applicable.
  • In the Investigator's judgment, subject is mentally competent to provide to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • Subjects with known or suspected ileus, severe ulcerative colitis, gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis or megacolon.
  • Subjects with ongoing severe, acute inflammatory bowel disease.
  • Subjects who had previous significant gastrointestinal surgeries.
  • Subjects with uncontrolled pre-existing electrolyte abnormalities, or those with electrolyte abnormalities based on Visit 1 laboratory results.
  • Subjects with uncontrolled hypertension (systolic blood pressure > 170 mmHg and diastolic blood pressure > 100 mmHg).
  • Subjects with severe renal insufficiency ( \< 30 mL/min/1.73m2).
  • Subjects with known severe hepatic insufficiency ( C).
  • Subjects with cardiac insufficiency ( Functional Classifications 3 or 4).
  • Subjects undergoing insulin therapy for any indication.
  • Subjects with impaired consciousness that predisposes them to pulmonary aspiration.
  • Subjects undergoing colonoscopy for foreign body removal and/or decompression.
  • Subjects who are pregnant or lactating, or intending to become pregnant during the study.
  • Subjects of who refuse a pregnancy test.
  • Subjects allergic to any preparation components.
  • Subjects who, in the opinion of the Investigator, should not be included in the study for any reason, including inability to follow study procedures.
  • Subjects who have participated in an surgical, drug, or device study within the past 30 days.
  • Subjects who withdraw consent before completion of Visit 1 procedures.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
121 participants (actual)

Study arms

  • Experimental
    BLI4900

    BLI4900 Bowel Preparation

    Drug: BLI4900

  • Active comparator
    PEG Control

    Polyethylene glycol-based bowel preparation

    Drug: PEG Control

Interventions

  • DrugBLI4900

    BLI4900 Bowel Preparation

  • DrugPEG Control

    Polyethylene glycol-based bowel preparation

06

What researchers measure

Primary outcomes

  1. % of Subjects With Successful Bowel Preparation

    % of subjects with successful bowel preparation rated by blinded colonoscopist on a 4 point scale (1=poor to 4 = excellent)

    Time frame: Day of colonoscopy

07

Results

Posted Oct 24, 2023

Participant flow

Participant flow — Overall Study
MilestoneBLI4900-3BLI4900-5BLI4900-6PEG-SD
Started21404119
Completed21404019
Not completed0010

Outcome measures

Primary% of Subjects With Successful Bowel Preparation

% of subjects with successful bowel preparation rated by blinded colonoscopist on a 4 point scale (1=poor to 4 = excellent)

Time frame:
Day of colonoscopy
Reported as:
Count of participants · Participants
% of Subjects With Successful Bowel Preparation
ParticipantsBLI4900-3BLI4900-5BLI4900-6PEG-SD
% of Subjects With Successful Bowel Preparation17373716

Adverse events

Collected over 2 days. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BLI4900-30/21 (0%)0/21 (0%)13/21 (61.9%)
BLI4900-50/40 (0%)0/40 (0%)31/40 (77.5%)
BLI4900-60/41 (0%)0/41 (0%)13/41 (31.7%)
PEG-SD0/19 (0%)1/19 (5.3%)14/19 (73.7%)
Most frequent serious events
Most frequent serious events
EventBLI4900-3BLI4900-5BLI4900-6PEG-SD
diverticulitisGastrointestinal disorders0/210/400/411/19
Most frequent other events
Most frequent other events
EventBLI4900-3BLI4900-5BLI4900-6PEG-SD
abdominal distensionGastrointestinal disorders11/2126/408/4110/19
nauseaGastrointestinal disorders7/2119/405/417/19
abdominal pain upperGastrointestinal disorders7/2117/406/415/19
vomitingGastrointestinal disorders3/212/403/411/19
headacheNervous system disorders2/210/400/410/19
hypernatremiaMetabolism and nutrition disorders0/210/400/411/19
migraineNervous system disorders1/210/400/410/19
orthostatic hypotensionVascular disorders1/211/400/410/19

Baseline characteristics

Age, Continuous
Age, Continuous(years)BLI4900-3BLI4900-5BLI4900-6PEG-SDTotal
Mean54.8 ± 11.154.5 ± 11.558.7 ± 10.249.7 ± 15.755.2 ± 12.0
Sex: Female, Male
Sex: Female, Male(Participants)BLI4900-3BLI4900-5BLI4900-6PEG-SDTotal
Female1020241266
Male112016754
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)BLI4900-3BLI4900-5BLI4900-6PEG-SDTotal
Hispanic or Latino5115728
Not Hispanic or Latino1639251292
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)BLI4900-3BLI4900-5BLI4900-6PEG-SDTotal
American Indian or Alaska Native00000
Asian406414
Native Hawaiian or Other Pacific Islander02204
Black or African American00314
White1738291498
More than one race00000
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(Participants)BLI4900-3BLI4900-5BLI4900-6PEG-SDTotal
United States21404019120
08

Study locations

4 sites
  • Braintree Research Site 1
    Anaheim, California 92801, United States
  • Braintree Research Site 3
    Chula Vista, California 91910, United States
  • Braintree Research Site 4
    San Diego, California 92114, United States
  • Braintree Clinical Research Site 2
    Ogden, Utah 84405, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2017 to primary completion in Nov 2019, 24 months.

Results were first posted in Oct 2023, 3 years 11 months after primary completion. A results delay was requested in Jan 2021.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2017
First posted
Nov 1, 2017
StartActual
Nov 9, 2017
Primary completionActual
Nov 12, 2019
CompletionActual
Nov 12, 2019
Results delay requested
Jan 26, 2021
Results first posted
Oct 24, 2023
Last update
Oct 24, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03328507
Responsible party
Sponsor
First posted
Nov 1, 2017
Start date
Nov 9, 2017
Primary completion
Nov 12, 2019
Completion
Nov 12, 2019
Results posted
Oct 24, 2023
Last update
Oct 24, 2023

Study contacts

John McGowan, MPH
study director · Braintree Laboratories, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion